Goodwin Procter has advised Merida Biosciences. Ropes & Gray has advised Eli Lilly and Company. Eli Lilly and Company (NYSE: LLY) and Merida Biosciences, Inc. have...
Eli Lilly to Acquire Merida Biosciences for Up To $2.875 Billion
Braveheart Bio Raises $439.9 Million in Upsized Initial Public Offering
Goodwin Procter and Wilson Sonsini Goodrich & Rosati have advised Braveheart Bio. Braveheart Bio, a clinical-stage biopharmaceutical company developing therapeutics for hypertrophic cardiomyopathy (HCM) and other...
Parabilis Medicines Completes $770 Million Upsized IPO and $75 Million Private Placement
Goodwin Procter has advised Parabilis Medicines. Covington has advised the underwriters. Parabilis Medicines, Inc., a clinical-stage biopharmaceutical company, has completed an upsized initial public offering, raising...
Gilead to Acquire Tubulis in $5 Billion Oncology-Focused Transaction
Covington has advised Gilead Sciences, Inc. CMS and Goodwin Procter have advised Tubulis GmbH. Gilead Sciences, Inc. has entered into a definitive agreement to acquire Tubulis...
Novartis Acquires Pikavation Therapeutics and PI3K? Inhibitor Portfolio from Synnovation for Up to $3 Billion
Goodwin Procter and Mintz have advised Synnovation Therapeutics on the transaction. Novartis has entered into a definitive agreement to acquire Pikavation Therapeutics, Inc., a wholly-owned subsidiary...
Enavate Sciences Invests in Braveheart Bio’s $185 Million Series A Financing
Wilmer Cutler Pickering Hale and Dorr has advised Enavate Sciences. Goodwin Procter has advised Braveheart Bio. Enavate Sciences, a platform of Patient Square Capital, has made...
Prime Medicine Closes $144 Million Public Offering of Common Stock
Goodwin Procter, Foley Hoag, Honigman, and Wilson Sonsini Goodrich & Rosati have advised Prime Medicine Inc. on the offering, and Paul Hastings has advised the underwriters....
Merck’s $3.9 Billion Acquisition of SpringWorks Therapeutics
Sullivan & Cromwell advised Merck KGaA, Darmstadt, Germany, while Goodwin Procter advised SpringWorks Therapeutics on the transaction. Skadden advised Centerview Partners and Goldman Sachs & Co....
Sanofi’s $40 Million Investment in Vigil Neuroscience
Ropes & Gray advised Sanofi on the transaction, and Goodwin Procter advised Vigil Neuroscience. Sanofi (Nasdaq: SNY) has made a $40 million strategic investment in Vigil...
Prime Medicine’s $161.0 Million Common Stock Offering
Goodwin Procter advised Prime Medicine and Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the transaction, while Davis Polk & Wardwell...
Isomorphic Labs’ Multi-Target Research Collaboration with Novartis
Goodwin advised Isomorphic Labs on its strategic research collaboration with Novartis. Isomorphic Labs has signed a strategic research collaboration with Novartis to discover small molecule therapeutics against...
Novo Nordisk’s Research Collaborations with Omega Therapeutics and Cellarity
Goodwin advised Flagship Pioneering on the matter. Hogan Lovells acted for Omega Therapeutics, Inc. Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) and Cellarity Inc. announced that Novo Nordisk...